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ABSTRACT: The objective of this study is to systematically review the relationship between lower-extremity 
peripheral nerve function and mobility in older adults. The National Library of Medicine (PubMed) was 
searched on March 23, 2015 with no limits on publication dates. One reviewer selected original research studies 
of older adults (≥65 years) that assessed the relationship between lower-extremity peripheral nerve function 
and mobility-related outcomes. Participants, study design and methods of assessing peripheral nerve 
impairment were evaluated and results were reported and synthesized. Eight articles were identified, including 
6 cross-sectional and 2 longitudinal studies. These articles investigated 6 elderly cohorts (4 from the U.S. and 2 
from Italy):  3 community-dwelling (including 1 with only disabled women and 1 without mobility limitations 
at baseline), 1 with both community-dwelling and institutionalized residents, 1 from a range of residential 
locations, and 1 of patients with peripheral arterial disease. Mean ages ranged from 71-82 years. Nerve function 
was assessed by vibration threshold (n=2); sensory measures and clinical signs and symptoms of neuropathy 
(n=2); motor nerve conduction (n=1); and a combination of both sensory measures and motor nerve conduction 
(n=3). Each study found that worse peripheral nerve function was related to poor mobility, although 
relationships varied based on the nerve function measure and mobility domain assessed. Six studies found that 
the association between nerve function and mobility persisted despite adjustment for diabetes. Evidence 
suggests that peripheral nerve function impairment at various levels of severity is related to poor mobility 
independent of diabetes. Relationships varied depending on peripheral nerve measure, which may be 
particularly important when investigating specific biological mechanisms.  Future research needs to identify 
risk factors for peripheral nerve decline beyond diabetes, especially those common in late-life and modifiable.  
Interventions to preserve nerve function should be investigated with regard to their effect on postponing or 
preventing disability in older adults. 
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Sensorimotor peripheral nerve function impairments are 
common in late-life. These impairments are an important 
risk factor for falls in both diabetic and nondiabetic 
individuals [1-5] and increasing evidence shows that they 
are associated with mobility limitations and disability. 
The National Health and Nutrition Survey found that 
reduced sensation at the foot is highly prevalent among 
those with and without diabetes, increasing from 8.1% at 
ages 40-49 to 34.7% after age 80 [6]. This is likely an 
underestimate of nerve impairment in the population due 
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to the use of less sensitive screening measures, limited to 
10-g monofilament screening and self-reported symptoms 
[7]. Clinical neuropathy rates also increase with age [8]. 
A population-based study of Italian elders showed the 
incidence of distal symmetric neuropathies (DSN) 
increased in participants without diabetes, from 4.6 to 8.8 
new cases per 1,000 person years, among those 65-79 to 
80-84 years of age, respectively. Incidence rates in 
participants with diabetes were higher, increasing from 
13.7 to 52.5 new cases per 1,000 person years from the 
65-79 to the 75-79 age groups, then dropping to 48.4 new 
cases within the 80-84 age group, likely due to a survival 
effect. Diabetes accounted for only 39.2% of prevalent 
neuropathy cases and 49% of incident cases [8], 
emphasizing the need to identify other etiologic pathways, 
particularly in non-diabetic older adults.  Clinical 
peripheral neuropathy is an important risk factor for 
disability and mobility limitations, particularly in older 
adults with diabetes [8-11] (www.cdc.gov/mmwr/ 
preview/mmwrhtml/mm5446a4.htm). Subclinical peri-
pheral nerve impairments are also associated with 
mobility limitations in older adults both with and without 
diabetes [12-15].   
We describe existing evidence on impaired lower-
extremity peripheral nerve function as a risk factor for 
mobility limitations with age. Evaluation of methods and 
findings available on this topic has important implications 
for designing interventions aimed at postponing or 
preventing disability in older adults. The aim of this 
systematic review is to evaluate the literature on lower-
extremity peripheral nerve function and mobility in 
studies of older adults, to identify knowledge gaps and 
provide recommendations for future research. 
 
MATERIALS AND METHODS 
 
The National Library of Medicine (PubMed) was 
searched on March 23, 2015 with no limits on publication 
dates. Figure 1 illustrates the search strategy, combining 
Medical Subject Heading (MeSH) terms and key words 
describing peripheral nerve function and mobility. We 
limited the search to “Aged: 65+ years” due to the 
dramatic increase in mobility limitations for this age 
group (www.cbo.gov/sites/default/files/108th-congress-
2003-2004/reports/04-26-longtermcare.pdf), the English 
language, and humans, yielding 127 articles. We 
evaluated the titles and abstracts of these and excluded 
articles that included: no lower-extremity peripheral nerve 
function assessment (n=52), no mobility-related outcome 
(n=10), neither of these (n=15), no statistical evaluation 
of the relationship between these measures (n=12), no 
original research (n=3 reviews, n=2 commentaries), case 
reports (n=4), and only rare conditions (n=11; see Fig. 1). 
Diabetic neuropathy is a well-recognized risk factor for 
mobility limitation [8-11] (www.cdc.gov/mmwr/ 
preview/mmwrhtml/mm5446a4.htm), so we excluded 
studies of diabetes only (n=11) in order to focus our 
review on more representative cohorts of older adults. We 
evaluated references from 7 articles and from review 
articles found during the search, resulting in 1 additional 
article. Eight articles were included. 
 
RESULTS 
 
The 8 articles on 6 separate cohorts included 6 cross-
sectional and 2 longitudinal analyses. Study details are 
summarized in Table 1. Five studies were conducted in 4 
U.S. populations, 3 of these community-dwelling, 
including 1 of disabled women (the Women’s Health and 
Aging Study - WHAS) and 2 from a population with no 
mobility limitations at baseline (the Health, Aging and 
Body Composition Study - Health ABC). The other 2 U.S. 
studies recruited subjects from various residential 
facilities (e.g. subsidized senior housing, retirement 
communities/homes within the Rush Memory and Aging 
Project) and patients with peripheral arterial disease 
(PAD) (the Walking and Leg Circulation Studies - 
WALCS/WALCS II). Three Italian studies included: 2 
from the same study of community-dwelling elderly 
(InCHIANTI); and 1 of both community-dwelling and 
institutionalized elderly (the Italian Longitudinal Study of 
Aging – ILSA). Mean ages across the studies ranged from 
71-82, with all participants aged ≥65 years, except for one 
study (aged ≥59 years). Studies assessed sensory and/or 
motor nerve function using varied techniques including: 
vibration detection threshold only (n=2) [12, 16]; sensory 
measures and clinical signs and symptoms of neuropathy 
(n=2) [14, 17]; motor nerve conduction only (n=1) [18]; 
and a combination of both sensory measures and motor 
nerve conduction (n=3) [15, 19, 20]. While 3 studies 
measured both sensory and motor peripheral nerve 
function, only 2 of these presented the results separately 
[15, 20]. Mobility outcomes were diverse and included: 
standing balance scores/ratios (n=3) [12, 15, 16]; usual-
paced (n=5) [12, 14-16, 19], fast-paced (n=1) [12], and 
narrow walking speed (n=1) [15]; chair stand 
ability/performance (n=2) [12, 15]; self-reported 
difficulty walking (n=1) [14]; physical performance 
battery score (n=3) [15, 17, 19]; self-reported walking and 
stair-climbing scores (n=1) [18]; the 36-Item Short Form 
Health Survey (SF-36) physical function scores (n=1) 
[18], and walking or stair-climbing difficulty/inability 
(n=1) [20]. 
A variety of methods that capture different domains of 
nerve function, such as sensory nerve function, which 
may be responsible for key somatosensory feedback for 
mobility postural control, and motor nerve function, 
which may provide information on muscle enervation, 
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were included. These common assessment techniques are 
described below. 
 
 
 
 
 
Figure 1. Flow diagram of search strategy for finding articles on the relationship between nerve function and 
mobility-related outcomes in older adults. 
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Table 1.  Summary of Studies on Peripheral Nerve Function and Mobility-Related Outcomes 
 
Author, 
Year 
Participants Mean Age ± SD 
(years) 
Design Sensory PN 
Measure(s) 
Motor PN 
Measure(s) 
Other PN Measure(s) 
Resnick et 
al., 2000[12] 
894 disabled community-
dwelling older women 
from WHAS, USA 
All ≥ 65 with more than 
one-quarter of 
the sample ≥ 85 (no 
mean ± SD provided) 
Cross-
sectional 
Vibration threshold 
(vibrating platform) 
  
Ferrucci et 
al., 2004[14] 
818 community dwelling 
older adults with no 
history of neurological 
disease from the 
InCHIANTI study, Italy 
All ≥ 65 (no mean ± SD 
provided)  
Cross-
sectional 
4.31 (2-g) and 4.56 
(4-g) monofilament; 
Vibration threshold 
(non-graduated 
tuning fork) 
  
Inzitari et 
al., 2006[17] 
1,052 older adults from 
ILSA, Italy 
71 ± 5; Range: 65-84 Prospective 
cohort with 
3 year 
follow-up 
Bilateral Achilles 
tendon reflex, touch 
and pinprick 
sensation* 
 Two phase screening for DSN: 1) 
symptoms, medications, brief 
neurologic exam (heal-to-toe 
gait, bilateral Achilles tendon 
reflex, light touch and pinprick); 
positive screenings proceeded to 
2) extensive neurologic exam, 
medical history, review of 
medical records when available 
(electromyography, sural nerve 
biopsy, blood and spinal fluid 
exam)* 
Strotmeyer  
et al., 
2008[15]  
2,364 black and white 
community dwelling 
older adults with and 
without diabetes with no 
mobility disability at 
baseline from the Health 
ABC Study, USA 
Men with diabetes  
76.8 ± 2.7;  
Men without diabetes 
76.7 ± 2.9; 
Women with diabetes 
76.1 ± 2.8; 
Women without 
diabetes 
76.5 ± 2.9; Range: 73-
82 
Cross-
sectional 
5.07 (10-g) and 4.17 
(1.4-g) 
monofilament; 
Vibration threshold 
(vibrating platform); 
 
Peroneal 
motor NCV 
and CMAP 
amplitude 
 
Buchman et 
al., 2009[16] 
629 older adults without 
dementia in residential 
facilities from the Rush 
Memory and Aging 
Project, USA 
81.8 ± 7.7 Cross-
sectional 
Vibration threshold 
(graduated tuning 
fork) 
  
Evans et al., 
2011[18] 
462 patients with PAD 
from WALCS and 
WALCS II, USA 
75.0 ± 8.3; all ≥ 59 at 
baseline with nerve 
measures at 4th annual 
follow-up 
Cross-
sectional 
 Peroneal 
motor NCV 
 
Chiles et 
al., 2014[19] 
983 community dwelling 
older adults from the 
InCHIANTI study, Italy 
Participants with: 
No diabetes 
74.6 ± 7.4; 
Impaired fasting 
glucose 
74.8 ± 6.8; 
Diabetes 
75.4 ±7.5; all  ≥ 65 
Cross-
sectional 
4.31 (2-g) and 4.56 
(4-g) monofilament; 
Vibration threshold 
(non-graduated 
tuning fork)* 
 
Peroneal 
motor NCV 
Neuropathy score based on: 4.31 
(2-g) and 4.56 (4-g) 
monofilament; 
Vibration threshold (non-
graduated tuning fork); and 
Peroneal motor NCV 
Ward et al., 
2014[20] 
2,148 black and white 
community dwelling 
older adults with no 
mobility disability at the 
first nerve exam from the 
Health ABC Study, USA 
76.5 ± 2.9; Range: all 
70-79 at baseline (nerve 
measures occurred 3 
years after baseline) 
Prospective 
cohort with 
10 year 
follow-up 
5.07 (10-g) and 4.17 
(1.4-g) 
monofilament; 
Vibration threshold 
(vibrating platform).  
Neuropathy 
symptoms: 
numbness or 
tingling and aching 
or burning pain. 
Sensory neuropathy 
score based on: 5.07 
(10-g) and 4.17 
(1.4-g) 
monofilament; 
Vibration threshold 
Peroneal 
motor NCV 
and CMAP 
amplitude; 
Motor 
neuropathy 
score based 
on Peroneal 
motor NCV 
and CMAP 
amplitude 
Neuropathy score based on: 5.07 
(10-g) and 4.17 (1.4-g) 
monofilament; 
Vibration threshold (vibrating 
platform); Peroneal motor NCV 
and CMAP amplitude 
 
 
*These measures were only analyzed as part of a composite measure of poor nerve function/neuropathy; SD = standard deviation; PN = peripheral nerve; 
PAD = peripheral arterial disease; WHAS = Women’s Health and Aging Study; InCHIANTI = Invecchiare nel Chianti ; g = gram; ILSA = Italian 
Longitudinal Study on Aging; DSN = Distal Symmetrical Neuropathy; Health ABC Study = Health, Aging and Body Composition Study; NCV = nerve 
conduction velocity; CMAP = compound muscle action potential; WALCS = Walking and Leg Circulation Study. 
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Nerve Conduction Studies (NCS)  
 
NCS measure both motor and sensory nerves by 
electrically stimulating the nerve and evaluating the 
response using surface electrodes. Results include 
compound muscle action potential (CMAP for motor 
nerves) and sensory nerve action potential amplitude 
(SNAP for sensory nerves), the size of an evoked response 
from electrical stimulation of the nerve; and nerve 
conduction velocity (NCV), the speed at which the signal 
propagates down the nerve. Lower amplitudes may be 
indicative of a smaller number of functioning axons, while 
slower NCV may indicate loss of myelin sheath, which 
insulates the axon, and/or loss of the larger, faster 
conducting axons [21, 22] (www.ninds.nih.gov/disorders/ 
peripheralneuropathy/detail_peripheralneuropathy.htm). 
 
Monofilament detection 
 
Monofilament detection assesses sensory nerve function. 
Pressure is applied to the extremity (often the dorsum of 
the large toe since it is highly sensitive and not as prone 
to callous) with a thin nylon thread until the thread 
buckles. The participants are asked to report, often during 
multiple trials, if/when they feel the pressure is being 
applied. 
 
Vibration detection threshold 
 
Vibration detection threshold (or vibration threshold) 
measures sensory nerve function by resting the bottom of 
the large toe on a vibrating knob connected to the top of a 
platform. The vibration is increased until the participant 
reports feeling it. Another method is a quantitative tuning 
fork, which involves adjusting calibrated weights on the 
two arms of the fork, to change the vibration from a scale 
of 0 to 8 [23]. With this method, the participant reports 
when they no longer feel the vibration.  
 
Studies with cross-sectional mobility outcomes 
 
Results summarizing associations between peripheral 
nerve measures and cross-sectional mobility outcomes are 
presented in Table 2. Resnick and colleagues analyzed 
data from 894 WHAS participants, a cohort of disabled 
community-dwelling women aged ≥65 years at baseline 
[12]. Vibration threshold categorized peripheral nerve 
impairment based on age-specific normal values [24]: 
3.43 to <4.87 vibration units (vu; 0-6.5 vu=0-20 microns; 
www.physitemp.com/products/VibrationSensativity/) for 
mild, 4.87 to <6.31 vu for moderate, and ≥6.31 vu for 
severe [12]. Peripheral nerve impairment was related to 
poor balance (inability to tandem stand), (OR [95% CI]: 
2.21 [1.36-3.60], 1.95 [1.07-3.55], and 3.02 [1.65-5.51] 
for mild, moderate, and severe nerve impairment, 
respectively vs. normal nerve function; p<0.05). Slower 
usual-paced (means [no SD reported]: -0.08, -0.08, and -
0.15 m/s for mild, moderate, and severe nerve 
impairment, respectively, p<0.01 for pairwise 
comparisons) and fast-paced walking speeds (-0.13, -0.12, 
and -0.24 m/s for mild, moderate, and severe nerve 
impairment, respectively, p<0.01 for pairwise 
comparisons) were present in women with all levels of 
impairment. Inability to stand from a chair was only worse 
in women with severe nerve impairment (OR [95% CI]: 
3.62 [1.99-6.54]). Models were adjusted for age, self-
reported diabetes, BMI, vision, arthritis, and history of 
stroke. Diabetes (n=165, 18.5%) was not associated with 
any mobility measure after adjustment for sensory 
impairments, suggesting that sensory impairments may 
partly explain the association between diabetes and 
mobility. Quadriceps strength (dynamometer) and poor 
balance attenuated 10%-28% of the association of nerve 
impairment with chair stand performance and 30%-60% 
of its association with walking speed (in terms of β), 
demonstrating some mediation from muscle function and 
balance, as may be expected. This study presented some 
of the first cross-sectional evidence suggesting 
impairments in sensory peripheral nerve function may be 
related to poor mobility. Limitations include that only 
sensory nerve function was measured, lack of longitudinal 
data, and evaluation of disabled women only. 
Ferrucci et al. investigated whether monofilament and 
tuning fork detection assessed by a neurologist were 
related to walking speed and self-reported ability to walk 
1 km in 818 Italian elders from the InCHIANTI study 
(≥65 years at baseline, no history of neurological disease) 
[14]. Adjusting for age and sex, inability to feel either the 
4.31 (2-g) or 4.56 (4-g) monofilament was associated with 
slower walking speed compared to the study sample 
average (% difference [95% CI]: -12% [-19%- -6%]) and 
inability to walk 1 km (OR [95% CI]: 2.9 [1.4-5.9]). 
Average walking speed was 1.04 m/s. This percent 
difference corresponds to 0.12 m/s, which exceeds the 
magnitude of clinically meaningful change and the 
difference associated with important outcomes like 
declines in self-reported mobility [25] and decreased 
survival [26]. Absent/reduced vibration threshold 
(vibration felt for <10 seconds [14]) measured with a 
tuning fork set to 128 Hz [14] was not associated with 
either mobility outcome. However, these tuning fork 
measures are not be able to detect subclinical declines and 
are largely clinical screening tools for major loss of 
sensation.  
Strotmeyer et al. assessed whether sensory and motor 
nerve function were related to mobility in 2,364 
community-dwelling white and black elderly with and 
without diabetes from the Health ABC Study (ages 70-79 
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at baseline) [15]. Sensory nerve function was assessed 
using average vibration threshold, and standard (10-g) and 
subclinical (1.4-g) monofilaments. Peroneal motor NCS 
were performed with stimulation at the popliteal fossa and 
fibular head and recording at the extensor digitorum 
brevis (highly reproducibly in a sample of these 
participants [27]). Better monofilament detection (10-
g/1.4-g) was associated with higher scores on a 
supplemented version of the lower-extremity battery from 
the Established Populations for the Epidemiologic Studies 
of the Elderly (EPESE) [28] (β=0.174, p=0.003), faster 
narrow walking speed (β=0.049, p=0.006), and faster 5 
repeated chair stand speed (β=0.015, p=0.007). Worse 
vibration threshold was associated with lower 
performance battery score (β= -0.004, p<0.001), slower 
usual walking speed (β= -0.0005, p=0.005), and lower 
standing balance ratio (β= -0.001, p<0.001). Higher 
CMAP amplitude was associated with higher 
performance battery score (β=0.105, p<0.001), faster 
usual walking speed (β=0.008, p=0.004), faster narrow 
walking speed (β=0.029, p<0.001), and higher standing 
balance ratio (β=0.014, p<0.001). Motor NCV was not 
associated with mobility. Models were adjusted for 
demographics, diabetes, body composition, lifestyle 
factors, and chronic conditions. These findings show that 
varied measures of peripheral nerve function may be 
associated with different components of mobility, though 
both sensory and motor nerve impairments were 
associated with the performance battery, usual and narrow 
walking speed, and balance. Adjustment for peripheral 
nerve function measures attenuated a proportion of the 
association of diabetes with poor mobility (20.8% for 
usual walking speed, 26.5% for standing balance ratio, 
25.1% for performance battery score, and 11.4% for 
narrow walking speed). The use of multiple measures of 
sensory and motor nerve function afforded the 
investigation of their varied relationships to mobility. 
However, sensory nerve conduction was not assessed and 
older adults with initial mobility limitation were not 
included. Nevertheless, these findings are generalizable to 
a racially diverse, well-functioning population at baseline. 
In 629 older adults from various residential facilities, 
the Rush Memory and Aging Project (age 81.8 ± 7.7 
years) measured vibration threshold using a graduated 
tuning fork [16]. Gait and balance parameters were 
analyzed from a factor analysis of the EPESE. Gait 
included time and steps to walk 8 feet and turn around and 
balance score included a one leg stand, toe stand, and 
tandem walk. Adjusting for demographics, the ability to 
discriminate vibration at lower intensities was associated 
with a better balance score (β=0.067, p<0.001) and faster 
gait speed (β=0.045, p=0.005), although the association 
with gait speed was attenuated to nonsignificant when 
adjusting for BMI, physical activity, chronic conditions 
(including diabetes), and history of falls. Adjusting for 
diabetes alone did not affect the association between 
vibration threshold and balance or gait speed. Vibration 
threshold was not associated with leg strength measured 
using hand-held dynamometers. However, hand-held 
dynamometers may be subject to error depending on the 
strength of the examiner, particularly when measuring 
lower-extremity strength [29, 30]. This study did not 
include a measure of motor nerve function, though 
supported the association between sensory nerve function 
and balance.  
Evans and colleagues performed peroneal motor NCS 
with stimulation at the popliteal fossa (recording site not 
reported) in 462 patients (age ≥59 years at baseline) with 
PAD (ankle brachial index <0.9) from WALCS/WALCS 
II [18]. Adjusting for age and sex, worse NCV quartile 
scores were associated with lower SF-36 physical 
function scores (worst to best: 38.8, 50.2, 53.9, 52.2, p-
trend<0.001), lower Walking Impairment Questionnaire 
(WIQ) speed scores (worst to best: 29.0, 37.4, 35.4, 41.0, 
p-trend=0.003), and lower stair-climbing scores (worst to 
best: 36.4, 43.6, 47.3, 50.6, p-trend=0.001). Worse CMAP 
amplitude quartile scores were associated with lower SF-
36 physical function scores (worst to best: 41.1, 48.4, 
52.5, 52.6, p-trend<0.001), lower WIQ walking distance 
scores (worst to best: 33.4, 38.4, 43.8, 41.8, p-
trend=0.03), and lower stair-climbing scores (worst to 
best: 35.2, 46.5, 48.8, 46.4, p-trend=0.007). Results 
remained consistent when adjusting for lifestyle factors, 
diabetes, and other chronic conditions. Importantly, 
persons with severe PAD typically have worse peripheral 
nerve function [31] and poorer lower-extremity 
performance [32]; however, these relationships are 
understudied in older adults. This study did not assess 
sensory nerve impairments, an important limitation since 
these also may affect mobility. 
Chiles et al. calculated neuropathy scores in a further 
analysis of the InCHIANTI study [19]. Impairments on 
the following peripheral nerve function tests were 
summed, assigning 1 point for each impairment for a total 
possible score of 5: peroneal motor NCV <40 m/s 
(stimulation and recording sites not specified), CMAP 
amplitude <3 mV, inability to feel the 4.31 (2-g) 
monofilament, inability to feel the 4.56 (4-g) 
monofilament, and absent/reduced vibration threshold 
(felt for <10 seconds [14]) with a tuning fork [14]. They 
also evaluated NCV continuously and found that worse 
velocity was associated with lower SPPB scores (β=0.05, 
p<0.05) but not slower gait speed, while worse summed 
neuropathy scores were associated with both lower SPPB 
scores (β= -0.94 for 2 vs. 0-1; β= -2.42 for ≥3 vs. 1; both 
p<0.01) and slower gait speed (β= -0.10 for 2 vs. 0-1; β= 
-0.15 for ≥3 vs. 1; both p<0.01), adjusting for 
demographics, BMI, smoking status, and diabetes. The 
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association between diabetes and SPPB was attenuated by 
8% when adjusted for NCV, by 19% when adjusted for 
neuropathy score, and by 33% when adjusted for both, 
although diabetes remained significant in all models. 
These findings provide additional support that peripheral 
nerve function may partially mediate the relationship 
between diabetes and poor mobility. A global neuropathy 
score based on clinical cut points was more strongly 
associated with mobility than a single peripheral nerve 
function measure alone, although only NCV was 
evaluated separately. Poor neuropathy scores may be a 
sign of more severely impaired nerves, which may 
contribute more strongly to poorer mobility.  
 
 
 
Table 2. Summary of Results from Studies on Peripheral Nerve Function and Mobility-Related Outcomes 
Peripheral 
nerve 
measures 
Standing 
balance 
Usual 
paced 
walking 
speed  
Fast 
paced 
walking 
speed  
Narrow 
walking 
speed 
Chair 
stand 
ability, 
once 
Chair 
stand 
speed, 5 
repeated  
Self-
reported 
difficulty 
walking 
1 km 
SPPB/ 
PPB 
WIQ 
walking 
score 
WIQ 
stair 
climbing 
score 
SF-
36 
Mobility 
disability 
Neuropathy 
score 
 C[19]      C[19]    L[20] 
DSN        L[17]     
Sensory 
measures 
            
Vibration 
threshold 
(vibrating 
platform) 
C[12, 15] C[12, 15] C[12] 0[15] C[12] 0[15]  C[15]    L[20] 
Vibration 
threshold 
(graduated 
tuning fork) 
C[16] 0[16]           
Vibration 
threshold 
(non-
graduated 
tuning fork) 
 0[14]     0[14]      
2g/4-g 
monofilament 
detection* 
 C[14]     C[14]      
10-g 
monofilament 
detection 
0[15] 0[15]  C[15]  C[15]  C[15]     
Sensory 
neuropath 
score 
           L[20] 
Neuropathy 
symptoms 
           L[20] 
Motor 
measures 
            
Peroneal 
CMAP  
C[15] C[15]  C[15]  0[15]  C[15] C[18] C[18] C[18] L[20] 
Peroneal 
motor NCV 
0[15] 0[15, 19]  0[15]  0[15]  0[15], 
C[19] 
C[18] C[18] C[18]  
Motor 
neuropathy 
score 
           L[20] 
 
C = significant associations found with cross-sectional mobility. L= significant associations found with longitudinal mobility. 0 = no association found. 
Blank cell = no association assessed. *No distinction was made between results for different monofilament forces within the manuscript. SPPB = Short 
Physical Performance Battery; PPB = Physical Performance Battery; WIQ = Walking Impairment Questionnaire; SF-36 = 36-Item Short Form Health 
Survey; DSN = Distal Symmetrical Neuropathy; NCV = nerve conduction velocity. CMAP = compound muscle action potential. 
Studies with longitudinal mobility outcomes 
 
Results summarizing associations between peripheral 
nerve measures and longitudinal mobility outcomes are 
presented in Table 2. A subsample of participants from 
ILSA [17] were evaluated for DSN using a two phase 
screening process. Participants with a self-reported 
diagnosis of DSN or diabetes or ≥1 sign or symptom of 
neuropathy during the first phase underwent a full 
neurological exam.  Motor performance was calculated as 
a composite score from 0 (worst) to 14 (best) by summing 
the following items: time to stand from a chair, number of 
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times a participant could step up on a 23-cm step in 10 
seconds, tandem walk, standing on one leg, walking 
speed, and number of steps to turn 180°, as previously 
described [33, 34]. Motor performance decline over three 
years was defined continuously and dichotomously as a 
score difference above the 75th percentile (decliners) or 
below (non-decliners). In 1052 participants (age 71 ± 5 
years) with initially non-impaired motor performance 
(score of 14), Inzitari and colleagues found that signs and 
symptoms of DSN assessed during the screening phase 
predicted decline in motor performance score (β=0.73, 
p=0.001 for continuous decline; OR [95% CI]: 2.00 [1.03-
3.87] for decliners vs. non-decliners) after adjusting for 
demographics, diabetes, chronic conditions, ADL, and 
IADL (instrumental ADL). Clinical DSN was associated 
with poor motor performance, independent of diabetes, 
which has clinical relevance since older adults without 
diabetes may be less likely to be screened or have a full 
clinical assessment for neuropathy. While the screening 
for neuropathy was quite comprehensive in this study, the 
adoption of this method by other large studies is unlikely 
since it is time intensive, expensive, and requires a 
physician. The effects of subclinical peripheral nerve 
impairments were not studied. In addition, substantial 
attrition occurred between the two time points (33%), 
which may have resulted in retention bias. This study did 
not evaluate the effect of changes in nerve function over 
time, though was important in showing that initial DSN 
predicted mobility decline over time. 
A longitudinal analysis within the Health ABC study 
investigated whether sensory and motor peripheral nerve 
function predicted incident mobility disability, defined as 
two consecutive self-reports of “a lot of difficulty/ 
inability” to walk a one-quarter of a mile or climb 10 steps 
[20, 35]. Participants were 2,148 community-dwelling 
older adults (mean age 76.5 ± 2.9) with no mobility 
disability at the 2000/01 nerve exam, which occurred 3 
years after baseline. Motor and sensory peripheral nerve 
function were measured as described within the cross-
sectional study. [15] Additionally, self-reported 
symptoms of numbness or tingling and sudden stabbing, 
burning pain, or deep aching in the legs or feet were 
included. Counts of sensory, motor, and combined 
sensory and motor nerve impairments were created using 
clinically meaningful values of 1) <1 mV for CMAP 
amplitude; 2) < 40 m/s for motor NCV; [21] 3) 1.4-g or 
10-g monofilament insensitivity; and 4) inability to detect 
vibration (threshold ≥131 μ). One standard deviation 
worse amplitude (HR=1.29, 95% CI=1.16–1.44) and 
vibration threshold (HR=1.13, 95% CI=1.04–1.23) and 
one (HR=1.34, 95% CI=1.11–1.63) and two symptoms 
(HR=1.65, 95% CI=1.26–2.17) were associated with 
incident mobility disability. These analyses adjusted for 
demographics, diabetes, body composition, chronic 
conditions, and lifestyle factors. Two motor (HR=2.10, 
95% CI=1.43–3.09), two sensory (HR=1.91, 95% 
CI=1.31–2.88), and ≥3 over all peripheral nerve 
impairments (HR=2.33, 95% CI=1.54–3.53) were 
associated with even higher hazards of incident mobility 
disability (vs. no impairments), adjusting for 
demographics, height, weight, and site. These findings 
support that multiple nerve function impairments may 
have a stronger effect on disability than individual nerve 
impairments alone. Quadriceps strength attenuated the 
relationship of mobility disability to vibration threshold 
(4%) and having two motor impairments (8%) to 
nonsignificant. Strength also attenuated having ≥3 nerve 
impairments (5%), although it remained a significant 
predictor of disability. Each of these nerve function 
measures significantly predicted strength, [36] and 
strength significantly predicted disability in all models, 
suggesting that it may be a mediator between nerve 
impairment and mobility disability. The interaction 
between diabetes and 1.4-g monofilament detection was 
significantly associated with disability (HR=1.48, 95% 
CI=1.02–2.16). The 1.4-g monofilament is typically used 
to detect subclinical sensory impairment and is not often 
used in examining individuals with diabetes; however, 
these findings suggest that it may be useful for identifying 
individuals with diabetes at risk of developing disability. 
Strengths of this study include the prospective cohort 
design, 10 years of follow-up capturing incident mobility 
disability, and the assessment of multiple domains of 
lower-extremity peripheral nerve function. Importantly, 
this study shows that lower-extremity peripheral nerve 
function impairment precedes mobility disability. This 
study was limited in that nerve function was only analyzed 
at one time point and therefore the effects of the duration 
of nerve impairment were not assessed. In addition, this 
study did not measure sensory nerve conduction and 
analyses were limited to older adults with no initial 
mobility limitation. 
 
DISCUSSION 
 
This systematic review presents evidence from 8 
epidemiologic studies, 6 cross-sectional and 2 
longitudinal studies of older adults showing that poor 
sensory and motor peripheral nerve function are 
associated with and predict poor physical function and 
mobility disability. Both sensory and motor peripheral 
nerve function were associated with standing balance 
scores/ratios, [12, 15, 16] usual [12, 14-16, 19] and 
narrow gait speed [15], performance battery scores, [15, 
17, 19] and mobility disability [20]. Older adults both with 
and without diabetes experience a high incidence and 
prevalence of poor nerve function and overt neuropathy 
[6, 8]. In one study of adults with a mean age of 76.5 years 
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and no mobility disability at baseline, 55% had ≥1 
peripheral nerve impairment initially and approximately 
half of these individuals had no neuropathy symptoms 
[20]. By the end of the 10-year follow-up, 30% of this 
study population developed mobility disability. Findings 
from this review suggest that much of the impaired nerve 
function among older adults that may lead to mobility 
decline may go undetected, particularly among those 
without diabetes who are not considered traditionally 
high-risk.  
Importantly, the relationship between nerve function 
and mobility appears to be mostly consistent across varied 
levels of peripheral nerve impairment severity [12], 
different populations, subgroups of older adults, and 
different methods of measuring of mobility [14, 15]. Of 
the studies that were able to assess the effects of sex [14-
20] and race [15, 18, 20] on the relationship, none reported 
significant differences, although only the effects of white 
and black race were investigated. More data is needed 
among additional ethnic groups. Several studies indicate 
that peripheral nerve impairments may partially explain 
the association with diabetes and poor mobility [12, 15, 
19]. In 6 studies, peripheral nerve function was associated 
with mobility independent of diabetes, emphasizing the 
importance of investigating additional risk factors for 
impaired nerve function.  Clinically diagnosed peripheral 
neuropathy is a well-known risk factor for poor mobility 
in individuals with diabetes [8-11] (www.cdc.gov/mmwr/ 
preview/mmwrhtml/mm5446a4.htm); although our 
review indicates that advanced age is an important risk 
factor for poor nerve function, independent of diabetes [6, 
8]. In addition, older adults with poor peripheral nerve 
function in combination with certain comorbidities, such 
as PAD may represent important high-risk groups towards 
which interventions should be focused.  
Findings suggest that a greater burden of sensory and 
motor nerve impairments may lead to worse mobility 
compared to individual impairments alone. Evidence also 
suggests that poor nerve function may even be detrimental 
at subclinical levels [12, 14, 15, 20], although more 
longitudinal data from older adults with no to minimal 
impairments at baseline are needed as confirmation.  Two 
studies assessed composite neuropathy scores and found 
that these were positively associated with all mobility 
outcomes including usual paced walking speed [19], 
performance battery score [19], and mobility disability 
[20].  This is particularly important since chronic 
sensorimotor distal polyneuropathy, which affects both 
sensory and motor nerves, is recognized as one of the most 
common forms of neuropathy [37]. 
We found 3 conflicting findings in the literature upon 
which further examination may shed light on the effects 
of different methodological approaches to examining the 
nerve impairment-mobility relationship. First, peroneal 
motor NCV was related to the SPPB in one study [19] but 
was not related to a supplemented version of the EPESE 
SPPB in another study [15]. The supplemented Health 
ABC version of the EPESE SPPB captures a wider range 
of function by including additional measures to overcome 
the ceiling effect of the original battery. Therefore it is 
unlikely that the lack of relationship is due to the use of 
the supplemented SPPB. Perhaps the adjustment of more 
chronic conditions attenuated the relationship by 
accounting for important explanatory factors. In addition, 
a number of measurement and physiological factors (e.g., 
lower limb temperature) may influence the reliability of 
NCS measures [27, 38]. Some factors can be minimized, 
even in older populations, by using standardized clinical 
measurement procedures [27, 38]. Despite this, NCV may 
be subject to more measurement variability than CMAP 
amplitude due to variations in temperature and height. 
Moreover, more missing data may occur for NCV than for 
amplitude. Among adults age ≥80 years, 25% and 40% 
may exhibit absent NC responses at the peroneal and sural 
nerves, respectively [39]. Further review of an absent 
response is needed to determine whether it resulted from 
difficulty in stimulation or truly impaired nerve function 
[39]. Upon evidence of truly impaired nerve function, a 
value of 0 may be assigned to the amplitude. However, 
with an absent CMAP response, NCV is not able to be 
obtained and therefore has missing data. 
Second, vibration threshold was associated with usual 
gait speed when assessed using a vibrating platform [15], 
which quantifies a wide range of sensory nerve function 
(e.g. ability to feel 0-131 microns) but not when using a 
standard non-quantitative tuning fork [14]. The 
relationship between vibration threshold assessed with a 
graduated tuning fork, which quantifies sensory nerve 
function using a smaller scale (0-8), and usual gait speed 
was attenuated to nonsignificant when adjusted for BMI, 
physical activity, chronic conditions, and history of falls 
[16]. Similarly, monofilament detection was associated 
with usual gait speed when using the more sensitive 2-g 
and 4-g threads [14], but not when using the standard 10-
g thread [15]. These findings may indicate a need for more 
rigorous testing to detect subclinical impairments when 
predicting mobility decline. Sensitive methodology may 
become particularly important when analyzing 
longitudinal data in order to capture changes in nerve 
function.  
Methods of peripheral nerve assessment vary in testing 
time, expense of equipment, training requirements of the 
examiner, and practicality of implementation in large 
studies. NCS are an objective and reliable method of 
assessing nerve function [27, 40-42] and the most 
quantitative method to detect peripheral neuropathy non-
invasively. [7] However, equipment for NCS is 
expensive, measurement is relatively time consuming 
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(e.g. 20-30 minutes per nerve), and requires a well-trained 
examiner and board-certified physician to interpret certain 
data. Furthermore, absent responses may present analytic 
challenges since it is not always clear whether these 
results are due to difficulty in stimulation or truly 
impaired nerve function [39]. However, absent sural 
responses were associated with more severe diabetic 
peripheral neuropathy assessed by vibration threshold in 
diabetic younger adults (mean ages 44.7 ± 1.02 to 48.5 ± 
1.11 years) [43]. Future work is needed to extend these 
findings to older adults. While NCS are considered “gold 
standard” measures clinically, limitations may exist to 
using these in older adults for longitudinal changes in 
nerve function. 
Other methods of assessing nerve function may be 
more economical and less time intensive but are limited 
to assessing sensory nerve function, such as monofilament 
detection and vibration threshold.  These measures 
typically require the participant to report feeling the 
stimulation and are therefore subjective.  Methods range 
in sensitivity, quantitative capacity, and predictiveness. 
Standard 10-g monofilament testing is used clinically to 
predict diabetic foot ulceration [44], whereas light-touch 
1.4-g and 2-g monofilament testing are generally used to 
detect subclinical impairment [45]. Lighter touch 
monofilaments, e.g. up to 4-g, may be more sensitive 
measures capable of detecting neuropathy earlier than the 
10-g monofilament [46]. Monofilament threads of 
varying pressure can be used in combination as a semi-
quantitative measure of touch sensation [47]. Vibration 
threshold measured using vibrating platforms quantify 
wide ranges of sensory nerve function (e.g. ability to feel 
0-131 microns). Some tuning forks can provide a 
quantitative measure of vibration threshold that has been 
shown to correlate with the SNAP amplitude [23].  Work 
by Oyer and colleagues suggests that categorizing tuning 
fork thresholds as 10 seconds or less can detect significant 
impairment in diabetic adults (ages of participants not 
reported) who exhibit normal 10-g monofilament 
detection [48]. Additionally, signs and symptoms may be 
used to measure poor nerve function, but may not be able 
to detect subclinical disease. 
Values of sensitivity and specificity should be assessed 
for a wide range of tests in older adults, particularly since 
they may have poor nerve function that is asymptomatic. 
Compared to NCS, 10-g monofilament testing had 77% 
sensitivity and 96% specificity detecting DSN, while 
vibration threshold had 53-80% sensitivity and 98-99% 
specificity, although these were performed in younger to 
middle aged adults (ages 37.6 ± 10.4 to 57.7 ± 10.1 years) 
[7] with and without diabetes and/or neuropathy, not in 
older adults. A study of middle aged adults with diabetic 
peripheral neuropathy (ages 53 ± 3.6 years) and younger 
healthy controls (ages 33 ± 3.2 years) found that a 
combination of thermal sensitivity and vibration threshold 
had optimum values of sensitivity (92-95%) and 
specificity (77-86%) for detecting peripheral neuropathy 
when comparing thermal, vibration, and monofilament 
testing [49]. Thermal sensitivity, is primarily mediated by 
thinly myelinated or unmyelinated small nerve fibers, 
while the previously described tests assess peripheral 
nerve function that is primarily mediated by large 
myelinated nerve fibers and some thinly myelinated fibers 
[49]. However, thermal testing is uncommon in studies of 
older adults. Moreover, little is known on how these tests 
perform in older adults with cognitive impairment.  
Many of the studies identified were limited to 
measuring sensory nerve function. These studies may not 
fully capture the relationship between nerve function and 
mobility since motor and sensory nerves may vary in their 
associations with measures of mobility and may be 
mediated by different mechanisms [15, 50, 51]. Poor 
motor nerve function may contribute to the observed 
reduction in size and number of muscle fibers, 
preferentially affecting type II fast twitch fibers [52] and 
may lead to declines in muscle density [51], a measure of 
muscle-fat infiltration and intracellular fat content in 
muscle [53]. These changes may precipitate declines in 
muscle strength and muscle power [54], though this has 
not been examined prospectively. Muscle power has been 
associated with peripheral nerve function in older men 
[50] and may be an important mechanism to assess when 
investigating its relationship with mobility since it 
captures both force and velocity, which are likely 
dependent on the number and firing rate of motor units 
[55]. Sensory nerve function may also impact mobility by 
affecting strength and power [50]. Evidence shows that 
experimentally blocking sensory input may lead to 
reduced maximal voluntary contractions [56], while 
somatosensory and cutaneous stimulation may result in 
short-term increases in strength and muscle activation [57, 
58]. The relationships between these different 
components of peripheral nerve and muscle function are 
not fully understood. Both motor and sensory nerve 
function parameters have also been associated with 
proprioception, which involves various muscle-, joint-, 
and cutaneous-mechanoreceptors [59].   Loss of 
proprioception has been linked to impaired balance 
performance [60] and falls [60, 61]. Although 
hypothesized to be primarily controlled by the sensory 
system, ankle inversion and eversion proprioception 
showed a strong association with peroneal CMAP, 
demonstrating the important link between motor and 
sensory nerve function [59].  The most common types of 
age-related and diabetic neuropathies affect both sensory 
and motor nerves, and therefore, it may be difficult to 
separate out the individual effects of each [37].  
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This review only assessed the relationship between 
measures of lower-extremity peripheral nerve function 
and common age-related declines in mobility, not exact 
etiology or mechanisms for these declines.  For instance, 
getting out of a chair may be heavily influenced by 
proximal neuropathies, which were not covered in this 
review.  However, more research is needed on the 
potential mechanisms in which nerve impairments may 
lead specifically to mobility limitations and disability. 
Mechanisms in the relationship between peripheral nerve 
impairments and mobility decline may guide potential 
therapeutic interventions. For instance, in middle aged to 
older adults with a range of peripheral nerve function, 
greater hip strength was found in those who had better 
balance than would be expected from their proprioceptive 
threshold and age [62]. These findings suggest that future 
work should examine hip strengthening as potential 
intervention to improve balance, particularly in older 
adults with impaired ankle proprioception.   
A number of additional gaps in the current literature 
need to be addressed. First, the relationships between 
lower-extremity peripheral nerve function and mobility in 
subgroups of older populations, such as different races 
and ethnicities, frail or institutionalized older adults and 
the young-old vs. the old-old, are unknown and should be 
assessed, particularly given the health disparities of 
disease-related risk factors for neuropathy. The 
performance of different nerve function measures should 
be evaluated among individuals with varying levels of 
cognitive impairment, particularly those that rely on more 
subjective assessment. Given that varied levels of severity 
of peripheral nerve impairment are associated with poor 
mobility outcomes, future work should quantify 
peripheral nerve function continuously rather than 
dichotomously. Focusing on a spectrum of impairment is 
particularly important for preventing the progression of 
nerve function decline and mobility impairments. In 
addition, small fiber sensory neuropathy, which manifests 
as a burning sensation in the feet and can be assessed by 
thermal sensitivity testing [49] and more advanced 
techniques such as corneal confocal microscopy [63], has 
been understudied in the context of late-life mobility 
decline and should be investigated. Limited longitudinal 
data on nerve function in older adults exists. Specifically, 
data from longitudinal cohort studies are needed to assess 
the duration effects of peripheral nerve impairment on 
mobility declines as well as potential mechanisms for the 
relationship such as muscle structure and function. 
Understanding the role of neuromuscular parameters in 
the disablement process may help identify multiple points 
of intervention. Interventions targeting individuals with 
poor and at risk for peripheral nerve function decline 
should be investigated, with the goal of preventing 
subsequent disability.  
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